NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P518)

Product Overview

Description

The antibody specifically binds to a human SEZ6 protein, use for the treatment, diagnosis or prophylaxis of neoplastic disorders.

Species Reactivity

Human; Mouse; Rat; Cynomolgus Monkey

Clonality

Monoclonal

Host Species

Humanized

Applications

FC; IHC; In Vitro; In Vivo

Relevant Diseases

Epilepsy

Product Properties

Formulation

PBS only

Preservatives

BSA Free

Concentration

1mg/mL

Purification

Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line

Purity

>95% by SDS PAGE or HPLC

Endotoxin Level

Regular Endotoxin < 5 EU/mg
Low Endotoxin < 1 EU/mg

Shipping

Gel Packs

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Research Use Only

For research use only

Target

SEZ6

Official Name

SEZ6

Full Name

Seizure Related 6 Homolog

Alternative Names

Seizure Related 6 Homolog; Seizure Related 6 Homolog (Mouse); Seizure Protein 6 Homolog; HSEZ-6; BSRPC; SEZ-6;

Gene ID

20370(Mouse); 192247(Rat)

Uniprot ID

Q7TSK2(Mouse)

Product Pictures

FuncS

Figure 1 shows the detection of SEZ6 protein expression in NTX tumor cells by flow cytometry using various anti-SEZ6 antibodies.

Axis corresponds to concentration of 3E antibody (Fab) and Y axis corresponds to NGF binding (percentage of maximal UR). Increasing concentrations of Fab E3 blocked the interaction of NGF with p75 and trkA, as indicated by a decrease in signal (measured in UR). When the concentration of E3 antibody (Fab) was equal to that of NGF, no NGF binding was observed (indicated by zero signal).

FuncS

Figure 2 shows the results of an in vitro disruption assay using anti-SEZ6 ADCs in HEK293 cells overexpressing SEZ6.

FuncS

Figure 3 shows the effect of anti-SEZ6 ADCs on the growth of SCLC (LU86) and LCNEC (Lu50) tumors in vivo.

FuncS

Figure 4 shows the ability of conjugated humanized anti-SEZ6 antibodies to delay the growth of four SCLC tumors (LU80, LU64, LU111 and LU117) in vivo and achieve durable remission in immunosuppressed mice.

FuncS

Figure 5 shows the ability of conjugated humanized anti-SEZ6 antibodies to delay the growth of four SCLC tumors (LU80, LU64, LU111 and LU117) in vivo and achieve durable remission in immunosuppressed mice.

Publications